Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
复制标题

DOI:
10.1016/j.jalz.2011.03.003
复制
发表时间:
2011-05
期刊:
Alzheimer's & dementia : the journal of the Alzheimer's Association
影响因子:
--
通讯作者:
Phelps CH
Phelps CH
中科院分区:
其他
文献类型:
--
作者:
Sperling RA;Aisen PS;Beckett LA;Bennett DA;Craft S;Fagan AM;Iwatsubo T;Jack CR Jr;Kaye J;Montine TJ;Park DC;Reiman EM;Rowe CC;Siemers E;Stern Y;Yaffe K;Carrillo MC;Thies B;Morrison-Bogorad M;Wagster MV;Phelps CH

文献摘要

参考文献

被引文献

相似文献

The pathophysiological process of Alzheimer's disease (AD) is thought to begin many years before the diagnosis of AD dementia. This long “preclinical” phase of AD would provide a critical opportunity for therapeutic intervention; however, we need to further elucidate the link between the pathological cascade of AD and the emergence of clinical symptoms. The National Institute on Aging and the Alzheimer's Association convened an international workgroup to review the biomarker, epidemiological, and neuropsychological evidence, and to develop recommendations to determine the factors which best predict the risk of progression from “normal” cognition to mild cognitive impairment and AD dementia. We propose a conceptual framework and operational research criteria, based on the prevailing scientific evidence to date, to test and refine these models with longitudinal clinical research studies. These recommendations are solely intended for research purposes and do not have any clinical implications at this time. It is hoped that these recommendations will provide a common rubric to advance the study of preclinical AD, and ultimately, aid the field in moving toward earlier intervention at a stage of AD when some disease-modifying therapies may be most efficacious.
DOI: 10.1001/archneurol.2009.27
发表时间: 2009-03
影响因子: --
作者:
Craft, Suzanne
通讯作者: Craft, Suzanne
DOI: 10.1093/cercor/bhn113
发表时间: 2009-03
期刊: CEREBRAL CORTEX
影响因子: 3.7
作者:
Dickerson, Bradford C.;Bakkour, Akram;Salat, David H.;Feczko, Eric;Pacheco, Jenni;Greve, Douglas N.;Grodstein, Fran;Wright, Christopher I.;Blacker, Deborah;Rosas, H. Diana;Sperling, Reisa A.;Atri, Alireza;Growdon, John H.;Hyman, Bradley T.;Morris, John C.;Fischl, Bruce;Buckner, Randy L.
通讯作者: Buckner, Randy L.
DOI: 10.1001/archneurol.2010.179
发表时间: 2010-08
影响因子: --
作者:
De Meyer, Geert;Shapiro, Fred;Vanderstichele, Hugo;Vanmechelen, Eugeen;Engelborghs, Sebastiaan;De Deyn, Peter Paul;Coart, Els;Hansson, Oskar;Minthon, Lennart;Zetterberg, Henrik;Blennow, Kaj;Shaw, Leslie;Trojanowski, John Q.
通讯作者: Trojanowski, John Q.
DOI: 10.1016/j.jalz.2011.03.004
发表时间: 2011-05
期刊: Alzheimer's & dementia : the journal of the Alzheimer's Association
影响因子: --
作者:
Jack CR Jr;Albert MS;Knopman DS;McKhann GM;Sperling RA;Carrillo MC;Thies B;Phelps CH
通讯作者: Phelps CH
DOI: 10.1001/archneurol.2007.27
发表时间: 2008-01-01
影响因子: --
作者:
Fotenos, Anthony F.;Mintun, Mark A.;Buckner, Randy L.
通讯作者: Buckner, Randy L.